Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Finished Goods (2016 - 2019)

Plus Therapeutics (PSTV) has disclosed Finished Goods for 9 consecutive years, with $1.7 million as the latest value for Q1 2019.

  • Quarterly Finished Goods fell 13.33% to $1.7 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2019, down 13.33% year-over-year, with the annual reading at $1.6 million for FY2018, 8.2% down from the prior year.
  • Finished Goods for Q1 2019 was $1.7 million at Plus Therapeutics, up from $1.6 million in the prior quarter.
  • The five-year high for Finished Goods was $2.5 million in Q4 2015, with the low at $1.5 million in Q1 2015.
  • Average Finished Goods over 5 years is $1.9 million, with a median of $1.8 million recorded in 2017.
  • The sharpest move saw Finished Goods plummeted 33.92% in 2015, then surged 50.79% in 2016.
  • Over 5 years, Finished Goods stood at $2.5 million in 2015, then decreased by 26.45% to $1.8 million in 2016, then decreased by 2.14% to $1.8 million in 2017, then fell by 8.2% to $1.6 million in 2018, then increased by 2.69% to $1.7 million in 2019.
  • According to Business Quant data, Finished Goods over the past three periods came in at $1.7 million, $1.6 million, and $1.7 million for Q1 2019, Q4 2018, and Q3 2018 respectively.